Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezolinetant 45 mg versus placebo for moderate to severe menopausal vasomotor symptoms in Chinese women
CTR20250084Phase 2Completed
- Sponsor
- 不适用/ 安斯泰来（中国）投资有限公司
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fezolinetant in vasomotor symptoms, sponsored by 不适用/ 安斯泰来（中国）投资有限公司. Started Apr 2025; status: completed.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on CTR20250084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250084.